Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. (31st October 2017)
- Record Type:
- Journal Article
- Title:
- Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema. (31st October 2017)
- Main Title:
- Health-economic evaluation of fluocinolone acetonide 190 µg implant in people with diabetic macular edema
- Authors:
- Holden, Sarah E.
Currie, Craig J.
Owens, David R. - Abstract:
- Abstract: Objectives: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. Methods: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation. Standard UK costs were attributed to healthcare resource use. Results: In total, 208 people contributing 233 FAc-treated eyes were selected. Mean age was 68.1 years and 62% were male. The mean (standard deviation, SD) number of anti-vascular endothelial growth factor (anti-VEGF) injections per FAc treated eye in the 12 months prior to implant was 2.8 (2.5), decreasing to 0.6 (1.4) for the same period after implant ( p < .001). The corresponding figures for other steroid injections (dexamethasone and triamcinolone) were 0.14 (0.4) before and 0.08 (0.4) after implant ( p = .016). There was no statistically significant difference in the number of laser therapies required in the 12 months before and after FAc implant (mean = 0.12 vs 0.11, respectively; p = .626). Overall, mean (SD) healthcare costs were £2, 691 (£1, 850) before and £1, 239 (£1, 203) after FAc implant ( p < .001). The unit drug and administration cost per FAc implant was £5, 680. Conclusions: Excluding the cost of theAbstract: Objectives: To assess healthcare resource use and costs of treating people with clinically significant diabetic macular edema (DME) with fluocinolone acetonide (FAc) 190 µg intravitreal implant in routine clinical practice. Methods: The retrospective Iluvien Clinical Evidence (ICE-UK) study collected data on people prescribed the FAc implant in any one of 13 ophthalmology centers between April 1, 2013 and April 15, 2015. Data were collected for 12 months before and after implantation. Standard UK costs were attributed to healthcare resource use. Results: In total, 208 people contributing 233 FAc-treated eyes were selected. Mean age was 68.1 years and 62% were male. The mean (standard deviation, SD) number of anti-vascular endothelial growth factor (anti-VEGF) injections per FAc treated eye in the 12 months prior to implant was 2.8 (2.5), decreasing to 0.6 (1.4) for the same period after implant ( p < .001). The corresponding figures for other steroid injections (dexamethasone and triamcinolone) were 0.14 (0.4) before and 0.08 (0.4) after implant ( p = .016). There was no statistically significant difference in the number of laser therapies required in the 12 months before and after FAc implant (mean = 0.12 vs 0.11, respectively; p = .626). Overall, mean (SD) healthcare costs were £2, 691 (£1, 850) before and £1, 239 (£1, 203) after FAc implant ( p < .001). The unit drug and administration cost per FAc implant was £5, 680. Conclusions: Excluding the cost of the FAc implant, healthcare costs were significantly reduced in the 12 months post - implant. FAc implant has a duration of 3 years. This needs to be considered when interpreting the cost associated with the FAc implant. … (more)
- Is Part Of:
- Current medical research and opinion. Volume 33(2017)Supplement 2
- Journal:
- Current medical research and opinion
- Issue:
- Volume 33(2017)Supplement 2
- Issue Display:
- Volume 33, Issue 2 (2017)
- Year:
- 2017
- Volume:
- 33
- Issue:
- 2
- Issue Sort Value:
- 2017-0033-0002-0000
- Page Start:
- 45
- Page End:
- 52
- Publication Date:
- 2017-10-31
- Subjects:
- Fluocinolone acetonide -- diabetic macular edema -- healthcare cost -- healthcare resource use -- retrospective
Clinical medicine -- Periodicals
Therapeutics -- Periodicals
615.5 - Journal URLs:
- http://informahealthcare.com ↗
- DOI:
- 10.1080/03007995.2017.1366663 ↗
- Languages:
- English
- ISSNs:
- 0300-7995
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3500.301000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 4601.xml